Richmond, VA, May 23, 2023 – Indivior PLC (LSE: INDV) today announced that its registration statement
on Form 20-F required for the additional U.S. listing of its ordinary shares is now available at
www.sec.gov and under the “Investors” section of the Company’s website (www.indivior.com). Trading
in Indivior’s ordinary shares on the NASDAQ Global Select Market is expected to commence at the open
on June 12, 2023, subject to approval by the U.S. Securities & Exchange Commission (SEC) and NASDAQ.
Indivior will retain its premium listing on the London Stock Exchange (LSE) and inclusion in the FTSE 250
index, and its ordinary shares will trade on both exchanges under the ticker symbol “INDV”. The
Company also notes that no shares are being offered as part of the additional U.S. listing.
Immediately prior to the additional U.S. listing, Indivior’s current American Depository Receipt (ADR)
program managed by J.P. Morgan (OTC US: INVVY) will be terminated. All Indivior American depository
shares representing Indivior shares will be mandatorily cancelled and exchanged for Indivior ordinary
shares on a 1:1 basis. Further information regarding this exchange process has been communicated
separately to ADR holders by J.P. Morgan.
Important Cautionary Note Regarding Forward-Looking Statements
This announcement contains certain statements that are forward-looking. Forward-looking statements include,
among other things, statements regarding the timing of our planned additional U.S. stock exchange listing and the
timing of the planned commercial launch of OPVEE, and other statements containing the words "believe",
"anticipate", "plan", "expect", "intend", "estimate", "forecast," "strategy," "target," "guidance," "outlook,"
"potential", "project", "priority," "may", "will", "should", "would", "could", "can", "outlook," "guidance", the
negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements
involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those expressed or implied in such statements because they relate to
future events. Various factors may cause differences between Indivior's expectations and actual results, including,
among others, the material risks described in the most recent Indivior PLC Annual Report and in subsequent
releases; our ability to commercialize and market acceptance of new products; the substantial litigation and
ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture
commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in
our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations,
requirements imposed by regulatory agencies and payment and reporting obligations under government pricing
programs; risks related to the manufacture and distribution of our products, some of which are controlled
substances; market acceptance of our products as well as our ability to commercialize our products and compete
with other market participants; the uncertainties related to the development of new products, including through
acquisitions, and the related regulatory approval process; our dependence on a small number of significant
customers; our ability to retain key personnel or attract new personnel; our dependence on third-party payors for
the reimbursement of our products and the increasing focus on pricing and competition in our industry;
unintended side effects caused by the clinical study or commercial use of our products; our use of hazardous
materials in our manufacturing facilities; our import, manufacturing and distribution of controlled substances; our
ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions;
our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings
related to intellectual property rights; the risks related to product liability claims or product recalls; the significant
amount of laws and regulations that we are subject to, including due to the international nature of our business;
macroeconomic trends and other global developments such as the COVID-19 pandemic; the terms of our debt
instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they
come due; changes in applicable tax rate or tax rules, regulations or interpretations; and our ability to realize our
deferred tax assets.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our
current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any
obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or
to reflect the occurrences of unanticipated events.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing
medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of
substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a
recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a
pipeline of product candidates designed to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and
cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than
1,000 individuals globally and its portfolio of products is available in 39 countries worldwide.
Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Media Contacts:
US Media:
Ben Atkins
Vice President, Communications
Indivior PLC
Tel: 424-844-3244
UK Media:
Teneo
Tel: +44 207-353-4200
Investors and Analysts:
Jason Thompson
Vice President, Investor Relations
Indivior PLC
Tel: 804-402-7123
Tim Owens
Director, Investor Relations
Indivior PLC
Tel: 804-263-3978
-ends-
Share